 |
 Video: What is a Stock Split?
|
|
|
| Ionis Pharmaceuticals is engaged in RNA-targeted therapeuty. Co.'s commercial products are SPINRAZA, TEGSEDI and WAYLIVRA. SPINRAZA injection for intrathecal use is a survival motor neuron-2 directed antisense medicine indicated for the treatment of spinal muscular atrophy in pediatric and adult patients. TEGSEDI injection is an RNA-targeted medicine indicated for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. WAYLIVRA is an antisense medicine indicated as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk for pancreatitis, in whom response to diet and triglyceride lowering therapy has been inadequate. According to our Ionis Pharmaceuticals stock split history records, Ionis Pharmaceuticals has had 0 splits. | |
|
Ionis Pharmaceuticals (IONS) has 0 splits in our Ionis Pharmaceuticals stock split history database.
Looking at the Ionis Pharmaceuticals stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Ionis Pharmaceuticals shares, starting with a $10,000 purchase of IONS, presented on a split-history-adjusted basis factoring in the complete Ionis Pharmaceuticals stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
04/28/2014 |
|
| End date: |
04/24/2024 |
|
| Start price/share: |
$31.55 |
|
| End price/share: |
$42.45 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
34.55% |
|
| Average Annual Total Return: |
3.01% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$13,451.12 |
|
| Years: |
10.00 |
|
|
|
|
|
